Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01596894
Recruitment Status : Completed
First Posted : May 11, 2012
Last Update Posted : August 10, 2017
Sponsor:
Information provided by (Responsible Party):
Prof. Arie Levine, Wolfson Medical Center

Tracking Information
First Submitted Date  ICMJE April 12, 2012
First Posted Date  ICMJE May 11, 2012
Last Update Posted Date August 10, 2017
Study Start Date  ICMJE October 2012
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 13, 2012)
Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle) [ Time Frame: 8 weeks ]
Original Primary Outcome Measures  ICMJE
 (submitted: May 9, 2012)
Response rate at 8 weeks defined as a drop in PCDAI of at least 12.5 points (or remission without steroids, intention to treat principle) [ Time Frame: 8 weeks ]
Change History Complete list of historical versions of study NCT01596894 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 8, 2017)
  • Normalization of CRP ( CRP ≤0.5 mg/dL). [ Time Frame: At week 8 ]
  • Fecal calprotectin at 8 weeks . [ Time Frame: 8 weeks ]
  • Remission at week 8 [ Time Frame: 8 weeks ]
Original Secondary Outcome Measures  ICMJE
 (submitted: May 9, 2012)
  • 1.CS free remission rate at 8 weeks . [ Time Frame: 8 weeks and 12 weeks ]
  • 2.Normalization of CRP ( CRP ≤0.5 mg/dL). [ Time Frame: Every 4 weeks (each visit) ]
  • 3.Fecal calprotectin at 8 weeks . [ Time Frame: 8 weeks ]
  • 4.CS free remission at 12 weeks. [ Time Frame: 12 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Official Title  ICMJE A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone.
Brief Summary The purpose of this study is to evaluate effectiveness of 2 months antibiotic course of Azithromycin combined with Metronidazole compared with 2 months antibiotic course of Metronidazole alone.
Detailed Description

Background: Recent reviews and guidelines no longer recommend antibiotic therapy for induction of remission in Crohn's disease (CD) due to studies showing lack of efficacy. Genetic and microbiological findings have demonstrated that CD is characterized by a defective innate immune response to bacteria and defective apoptosis of T cells. Bacteria have been shown to reside on, and invade epithelial cells, are present in granulomas and to replicate inside macrophage phagolysosomes in susceptible individuals. A defect in bacterial triggering from the luminal epithelial and intracellular compartments, while simultaneously trying to induce apoptosis, has never been explored. Azithromycin is an antibiotic with excellent intracellular penetration, high luminal concentrations, and is also effective against biofilms which have been described in CD. It is a potent activator of apoptosis of T cells. Preliminary data in pediatric patients with short duration of disease have shown a remission rate of 60% and normalization of CRP in about 50% of patients treated with azithromycin and metronidazole in combination. The investigators hypothesize that a 2-month antibiotic course of azithromycin combined with metronidazole is effective for inducing remission in active pediatric Crohns disease (CD). The investigators also hypothesize that remission will be accompanied by normalization of CRP in a high proportion of patients with active CD. The goal of the present study is to evaluate the efficacy of this combination in a randomized controlled trial (RCT).

Methods: This will be a single blinded multicenter randomized controlled trial in children with mild to moderate active CD (PCDAI≥10 ≤40) and elevated CRP, involving the terminal ileum and/or colon , comparing two arms over 8 weeks of therapy:

Group 1: Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks .Group 2: Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks . Four visits will take place at enrolment, and at 4, 8, and 12 weeks thereafter. In addition, there will be a telephone visit at 48 hours after commencement of therapy. Patients will be evaluated for PCDAI, Physicians Global Assessment (PGA) and CRP at each visit. The primary endpoint will be response rate at 8 weeks defined as a drop in PCDAI of at least 12.5 points (or remission). Secondary end points will include : 1.Remission rate at 8 weeks. 2. Normalization of CRP (CRP ≤0.5 mg/dL), 3. Fecal calprotectin at 8 weeks and 4. Corticosteroid free remission at 12 weeks.

Importance and anticipated outcomes: The investigators believe that high dose azithromycin will be associated with a high remission rate in early disease. If azithromycin based therapy is validated in an appropriate RCT, it would strengthen the premise that bacteria could, and possibly should be a therapeutic target in CD early in the disease. At a practical level an additional treatment that does not involve corticosteroids and does not suppress the immune system would be available for induction of remission. On a translational level, the underlying hypothesis which led to this treatment regimen, namely that bacteria in all compartments and apoptosis need to be targeted simultaneously, might have ramifications for how the disease should be treated. Theoretically, CD may be a chronic disease because the investigators do not simultaneously treat the two triggers for persistent inflammation (bacterial triggering and defective apoptosis), and ongoing inflammation allows continuous bacterial penetration.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Condition  ICMJE Crohn's Disease
Intervention  ICMJE
  • Drug: Azithromycin + Metronidazole
    Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
    Other Names:
    • Azanil
    • Flagyl
  • Drug: Metronidazole
    Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
    Other Name: Flagyl
Study Arms  ICMJE
  • Experimental: Azithromycin + Metronidazole
    Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
    Intervention: Drug: Azithromycin + Metronidazole
  • Active Comparator: Metronidazole
    Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
    Intervention: Drug: Metronidazole
Publications * Levine A, Kori M, Kierkus J, Sigall Boneh R, Sladek M, Escher JC, Wine E, Yerushalmi B, Amil Dias J, Shaoul R, Veereman Wauters G, Boaz M, Abitbol G, Bousvaros A, Turner D. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. Gut. 2019 Feb;68(2):239-247. doi: 10.1136/gutjnl-2017-315199. Epub 2018 Feb 2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 6, 2015)
73
Original Estimated Enrollment  ICMJE
 (submitted: May 9, 2012)
70
Actual Study Completion Date  ICMJE December 2015
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Children 5-17 years of age.
  2. Diagnosis of active Crohn's Disease.4. Patients with a PCDAI≥10 ≤40 (mild to moderate disease).
  3. Have involvement of the colon and/or terminal ileum.
  4. Disease defined as L1, L2, L3 or any of the above and may have gastric, duodenal or esophageal disease (L4a) according to the Paris classification for site of disease.
  5. The CRP ≥ 0.6 mg/dL.
  6. Duration of disease since diagnosis < 3 years.
  7. Negative stool culture, Clostridium Difficile Toxin from current flare.

Exclusion Criteria:

  1. Duration of disease since diagnosis > 3 years.
  2. Positive stool culture or O&P last 30 days.
  3. Presence of clostridium difficile toxin in stool.
  4. Azithromycin or Metronidazole allergy or known intolerance.
  5. Diagnosis of IBD -U.
  6. Presence of macroscopic disease involving the proximal ileum or jejunum (L4b).
  7. Continuous macroscopic disease of the colon appearing as typical ulcerative colitis and Crohns diagnosed only by focality or granuloma on biopsies.
  8. Presence of extraintestinal manifestations (such as arthritis, uveitis, or sclerosing cholangitis).Apthous lesions of mouth can be included.
  9. Presence of fibrostenotic disease (strictures with prestenotic dilatation).
  10. Presence of penetrating disease (fistulas or abscess).
  11. Presence of current perianal disease defined as fistula or abscess.
  12. Patients receiving concurrent corticosteroids or biologics.
  13. Patients who have received steroids in the past 14 days.
  14. Immune deficiency (CGD, GSD1, IL10R etc).
  15. Known allergy or intolerance to any of the study medications.
  16. Concurrent diseases such as hepatitis, ALT >2 times UNL, renal failure.
  17. Pregnancy.
  18. Patients with known heart disease.
  19. Prolonged QTc by E.C.G at baseline.
  20. Patient after surgical resection.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 5 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Israel
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01596894
Other Study ID Numbers  ICMJE 0035-12-WOMC
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Prof. Arie Levine, Wolfson Medical Center
Study Sponsor  ICMJE Prof. Arie Levine
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Arie Levine, MD Pediatric Gastroenterology and Nutrition Unit, The E. Wolfson MC, Tel-Aviv University, Holon, Israel
Study Director: Dan Turner, MD, PhD Pediatric Gastroenterology and Nutrition Unit, The Hebrew University of Jerusalem, Shaare Zedek MC, Jerusalem, Israel
Study Director: Athos Bousvaros, MD Bostons Childrens Hospital
Principal Investigator: Michal Kori, MD Kaplan Medical Center
Principal Investigator: Ron Shaoul, MD Rambam Health Care Campus
Principal Investigator: Eyath Wine, MD Women and Children's Health Research Institute, University of Alberta, Edmonton
Principal Investigator: Jorge Amil Dias, MD Hospital S. Joao, Porto, Porpugal
Principal Investigator: Gigi Wauters Veereman, MD Pedigastro, Antwerpen, Belgium
Principal Investigator: Malgorzata Margaret Sladek, MD, PhD Polish-American Children's Hospital
Principal Investigator: Richard Russell, MD Yorkhill Hospital, Glasgow, Scotland
Principal Investigator: Johanna C. (Hankje) , Escher, MD PhD Erasmus MC-Sophia Children's Hospital
PRS Account Wolfson Medical Center
Verification Date August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP